Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | MME | P08473 | 4/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23040110 | 1.00 | TGFBR1 (0.41) | TGFBR1MMEPDCD1LG2CD274ACE | |
| SCHEMBL29782938 | 0.88 | DPP4 (0.46) | MMEACESLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28996288 | 0.86 | TGFBR1 (0.55) | TGFBR1MMEPDCD1LG2CD274ACE | |
| SCHEMBL4958339 | 0.86 | TGFBR1 (0.55) | TGFBR1MMEPDCD1LG2CD274ACE | |
| SCHEMBL29528322 | 0.85 | DPP4 (0.44) | MMEACESLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18286555 | 0.85 | DPP4 (0.46) | MMEACESLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7757138 | 0.83 | ENPEP (0.43) | MME | |
| SCHEMBL30799360 | 0.83 | ENPEP (0.43) | MME | |
| SCHEMBL30997456 | 0.82 | TGFBR1 (0.52) | TGFBR1MMEPDCD1LG2CD274ACE | |
| SCHEMBL30997468 | 0.82 | TGFBR1 (0.52) | TGFBR1MMEPDCD1LG2CD274ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| EP-4021901-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | TGFBR1 2631/4885MME 4521/4885PDCD1LG2 440/4885 |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | TGFBR1 2631/4885MME 4521/4885PDCD1LG2 440/4885 |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | TGFBR1 2072/4885MME 4633/4885PDCD1LG2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.